General Information of Drug (ID: DMEP80Q)

Drug Name
4-cyanophenyl ethyl dodecylphosphonate Drug Info
Synonyms 4-cyanophenyl ethyl dodecylphosphonate; CHEMBL462582
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44563662
TTD Drug ID
DMEP80Q

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [2]
Thiopental DMGP8AX Anaesthesia 9A78.6 Approved [3]
JNJ-42165279 DM72GZO Anxiety disorder 6B00-6B0Z Phase 2 [4]
SSR411298 DMGTB2Q Major depressive disorder 6A70.3 Phase 2 [5]
IW-6118 DMP42W1 Inflammation 1A00-CA43.1 Phase 2 [6]
PF-04457845 DMPRYU1 Liver disease DB90-BD99 Phase 2 [7]
IPI-940 DMEIM5G Pain MG30-MG3Z Phase 1 [8]
PMID29053063-Compound-11d DMDRK68 N. A. N. A. Patented [9]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [9]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [10]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [11]
Orlistat DMRJSP8 Obesity 5B81 Approved [12]
SR141716A DMCO5JZ Obesity 5B81 Approved [13]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [14]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [15]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [16]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [17]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [18]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Fatty acid amide hydrolase (FAAH) TTDP1UC NOUNIPROTAC Inhibitor [1]

References

1 Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8.
2 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3 The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7 Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9 A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
10 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
11 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
12 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
13 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
14 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
15 Clinical pipeline report, company report or official report of AstraZeneca (2009).
16 Company report (Gwpharm)
17 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
18 Clinical pipeline report, company report or official report of Bird Rock Bio.
19 Clinical pipeline report, company report or official report of Affimed Therapeutics.